New drug IM-1617 enters human testing for advanced cancers
NCT ID NCT07578571
First seen May 13, 2026 · Last updated May 20, 2026 · Updated 2 times
Summary
This early-phase trial tests the safety of a new drug, IM-1617, in about 175 adults with advanced solid tumors (colorectal, lung, breast, stomach, esophageal, or other cancers that have spread or can't be removed by surgery). The study first finds a safe dose, then checks how well the drug works. It is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.